Genomic alterations and diagnosis of renal cancer

1.

Stewart GD, Klatte T, Cosmai L, Bex A, Lamb BW, Moch H, Sala E, Siva S, Porta C, Gallieni M (2022) The multispeciality approach to the management of localised kidney cancer. Lancet 400:523–534. https://doi.org/10.1016/S0140-6736(22)01059-5CrossRefPubMed

2.

Alaghehbandan R, Perez Montiel D, Luis AS, Hes O (2019) Molecular genetics of renal cell tumors: a practical diagnostic approach. Cancers (Basel) 12. https://doi.org/10.3390/cancers12010085

3.

Moch H, Amin MB, Berney DM, Comperat EM, Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Netto GJ (2022) The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 82:458–468. https://doi.org/10.1016/j.eururo.2022.06.016CrossRefPubMed

4.

Al-Obaidy KI, Eble JN, Nassiri M, Cheng L, Eldomery MK, Williamson SR, Sakr WA, Gupta N, Hassan O, Idrees MT, Grignon DJ (2020) Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol 33:1157–1164. https://doi.org/10.1038/s41379-019-0362-1CrossRefPubMed

5.

Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN (2020) Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC): a distinctive neoplasm associated with somatic NF2 mutations. Am J Surg Pathol 44:901–916. https://doi.org/10.1097/PAS.0000000000001467CrossRefPubMedPubMedCentral

6.

Farcas M, Gatalica Z, Trpkov K, Swensen J, Zhou M, Alaghehbandan R, Williamson SR, Magi-Galluzzi C, Gill AJ, Tretiakova M, Lopez JI, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Siadat F, Sangoi A, Gao Y, Ptakova N, Kuthi L, Pivovarcikova K, Rogala J, Agaimy A, Hartmann A, Fraune C, Rychly B, Hurnik P, Durcansky D, Bonert M, Gakis G, Michal M, Hora M, Hes O (2022) Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol 35:344–351. https://doi.org/10.1038/s41379-021-00923-6CrossRefPubMed

7.

Williamson SR, Hes O, Trpkov K, Aggarwal A, Satapathy A, Mishra S, Sharma S, Sangoi A, Cheng L, Akgul M, Idrees M, Levin A, Sadasivan S, San Miguel Fraile P, Rogala J, Comperat E, Berney DM, Bulimbasic S, McKenney JK, Jha S, Sampat NY, Mohanty SK (2023) Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity Histopathology 82:296–304. https://doi.org/10.1111/his.14816

8.

Al-Obaidy KI, Bridge JA, Cheng L, Sumegi J, Reuter VE, Benayed R, Hameed M, Williamson SR, Hes O, Alruwaii FI, Segal JP, Wanjari P, Idrees MT, Nassiri M, Eble JN, Grignon DJ (2021) EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. Mod Pathol 34:1921–1934. https://doi.org/10.1038/s41379-021-00833-7CrossRefPubMed

9.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Spellman PT, Rathmell WK, Linehan WM (2018) The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports 23:313-326.e315. https://doi.org/10.1016/j.celrep.2018.03.075CrossRefPubMed

10.

Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, The Cancer Genome Atlas Research N, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ (2014) The somatic genomic landscape of chromophobe renal cell carcinoma Cancer Cell 26:319-330. https://doi.org/10.1016/j.ccr.2014.07.014

11.

Sun G, Zhang X, Liang J, Pan X, Zhu S, Liu Z, Armstrong CM, Chen J, Lin W, Liao B, Lin T, Huang R, Zhang M, Zheng L, Yin X, Nie L, Shen P, Zhao J, Zhang H, Dai J, Shen Y, Li Z, Liu J, Chen J, Liu J, Wang Z, Zhu X, Ni Y, Qin D, Yang L, Chen Y, Wei Q, Li X, Zhou Q, Huang H, Yao J, Chen N, Zeng H (2021) Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma. Clin Cancer Res 27:1734–1743. https://doi.org/10.1158/1078-0432.CCR-20-3788CrossRefPubMed

12.

Board WCotE (2022) Classification of tumours of the urinary system and male genital organs. ed. 5 Lyon, France: International Agency for Research on Cancer

13.

Lawrie CH, Armesto M, Fernandez-Mercado M, Arestin M, Manterola L, Goicoechea I, Larrea E, Caffarel MM, Araujo AM, Sole C, Sperga M, Alvarado-Cabrero I, Michal M, Hes O, Lopez JI (2018) Noncoding RNA expression and targeted next-generation sequencing distinguish tubulocystic renal cell carcinoma (TC-RCC) from other renal neoplasms. J Mol Diagn : JMD 20:34–45. https://doi.org/10.1016/j.jmoldx.2017.09.002CrossRefPubMed

14.

Becker F, Junker K, Parr M, Hartmann A, Fussel S, Toma M, Grobholz R, Pflugmann T, Wullich B, Strauss A, Behnes CL, Otto W, Stockle M, Jung V (2013) Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS ONE 8:e78137. https://doi.org/10.1371/journal.pone.0078137CrossRefPubMedPubMedCentral

15.

Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, Choueiri T, Gallucci M, Sentinelli S, Fazio VM, Poeta ML, Liu S, Morrison C, Pili R (2016) Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget 7:29901–29915. https://doi.org/10.18632/oncotarget.9093

16.

Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, Kristiansen G, Lüders C, Nesi G, Compérat E, Sibony M, Berney DM, Mehra R, Brimo F, Hartmann A, Husain A, Frizzell N, Hills K, Maclean F, Srinivasan B, Gill AJ (2016) Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol 40:865–875. https://doi.org/10.1097/PAS.0000000000000617CrossRefPubMed

17.

Kuroda N, Tsutsui M, Iguchi M, Nobuoka E, Uehara T, Sonobe Y, Morinaga Y, Shibuya S, Oda W, Yanai H, Kawada C, Karashima T, Yamasaki I, Inoue K, Nagashima Y (2020) Fumarate hydratase-deficient renal cell carcinoma: a clinicopathological study of seven cases including hereditary and sporadic forms. Ann Diagn Pathol 49:151599. https://doi.org/10.1016/j.anndiagpath.2020.151599CrossRefPubMed

18.

Lu E, Hatchell KE, Nielsen SM, Esplin ED, Ouyang K, Nykamp K, Zavoshi S, Li S, Zhang L, Wilde BR, Christofk HR, Boutros PC, Shuch B (2022) Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. Cancer 128:675–684. https://doi.org/10.1002/cncr.33997CrossRefPubMed

19.

Wyvekens N, Valtcheva N, Mischo A, Helmchen B, Hermanns T, Choschzick M, Hotker AM, Rauch A, Muhleisen B, Akhoundova D, Weber A, Moch H, Rupp NJ (2020) Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach. Genes Chromosomes Cancer 59:611–619. https://doi.org/10.1002/gcc.22878CrossRefPubMed

20.

Hamza A, Sirohi D, Smith SC, Amin MB (2021) Low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma: an update on biologic potential, morphologic spectrum, and differential diagnosis with other low-grade oncocytic tumors. Adv Anat Pathol 28:396–407. https://doi.org/10.1097/PAP.0000000000000321CrossRefPubMed

21.

Mannan R, Wang X, Bawa PS, Chugh S, Chinnaiyan AK, Rangaswamy R, Zhang Y, Cao X, Smith SC, Trpkov K, Williamson SR, Sangoi AR, Mohanty S, McKenney JK, Gupta S, Magi-Galluzzi C, Argani P, Osunkoya AO, Chinnaiyan AM, Dhanasekaran SM, Mehra R (2023) Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma. Hum Pathol 134:102–113. https://doi.org/10.1016/j.humpath.2022.12.013CrossRefPubMed

22.

Zheng LM, Zhang XM, Pan XY, Zhou Q, Zeng H, Chen N (2023) AKR1B10 is a new sensitive and specific marker for fumarate hydratase-deficient renal cell carcinoma. Lab Invest 103:S840–S841

23.

Lau HD, Chan E, Fan AC, Kunder CA, Williamson SR, Zhou M, Idrees MT, Maclean FM, Gill AJ, Kao CS (2020) A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol 44:98–110. https://doi.org/10.1097/PAS.0000000000001372CrossRefPubMed

24.

Gill AJ (2018) Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology 72:106–116. https://doi.org/10.1111/his.13277CrossRefPubMed

25.

Tsai TH, Lee WY (2019) Succinate dehydrogenase-deficient renal cell carcinoma. Arch Pathol Lab Med 143:643–647. https://doi.org/10.5858/arpa.2018-0024-RSCrossRefPubMed

26.

Brunelli M, Delahunt B, Gobbo S, Tardanico R, Eccher A, Bersani S, Cossu-Rocca P, Parolini C, Balzarini P, Menestrina F, Cheng L, Eble JN, Martignoni G (2010) Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combining metaphase and interphase analyses. Am J Clin Pathol 133:116–126. https://doi.org/10.1309/AJCPSATJTKBI6J4NCrossRefPubMed

27.

Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM (2013) The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol 182:1163–1170. https://doi.org/10.1016/j.ajpath.2013.01.007CrossRefPubMed

28.

Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D’Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM, National Wilms Tumor Study G (2005) Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312–7321. https://doi.org/10.1200/JCO.2005.01.2799CrossRefPubMed

29.

Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanic G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O’Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K (2016) Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. J Clin Oncol 34:3195–3203. https://doi.org/10.1200/JCO.2015.66.0001CrossRefPubMedPubMedCentral

30.

Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ (2016) Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the Children’s Oncology Group. J Clin Oncol 34:3189–3194. https://doi.org/10.1200/JCO.2015.66.1140CrossRefPubMedPubMedCentral

31.

Zheng J (2013) Oncogenic chromosomal translocations and human cancer (review). Oncol Rep 30:2011–2019. https://doi.org/10.3892/or.2013.2677CrossRefPubMed

32.

Kuroda N, Trpkov K, Gao Y, Tretiakova M, Liu YJ, Ulamec M, Takeuchi K, Agaimy A, Przybycin C, Magi-Galluzzi C, Fushimi S, Kojima F, Sibony M, Hang JF, Pan CC, Yilmaz A, Siadat F, Sugawara E, Just PA, Ptakova N, Hes O (2020) ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol 33:2564–2579. https://doi.org/10.1038/s41379-020-0578-0CrossRefPubMed

33.

Wangsiricharoen S, Zhong M, Ranganathan S, Matoso A, Argani P (2021) ALK-rearranged renal cell carcinoma (RCC): a report of 2 cases and review of the literature emphasizing the distinction between VCL-ALK and non-VCL-ALK RCC. Int J Surg Pathol 29:808–814. https://doi.org/10.1177/10668969211003660CrossRefPubMed

34.

Cajaiba MM, Jennings LJ, George D, Perlman EJ (2016) Expanding the spectrum of ALK-rearranged renal cell carcinomas in children: identification of a novel HOOK1-ALK fusion transcript Genes Chromosomes. Cancer 55:814–817. https://doi.org/10.1002/gcc.22382CrossRef

35.

Hang JF, Chung HJ, Pan CC (2020) ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology. Virchows Arch 476:921–929. https://doi.org/10.1007/s00428-020-02752-5CrossRefPubMed

36.

Gallagher KPD, Roza A, Tager E, Mariz B, Soares CD, Rocha AC, Abrahao AC, Romanach MJ, Carlos R, Hunter KD, Lopes MA, Vargas PA, Santos-Silva AR (2023) Rhabdomyosarcoma with TFCP2 rearrangement or typical co-expression of AE1/AE3 and ALK: report of three new cases in the head and neck region and literature review. Head Neck Pathol. 17:546–561. https://doi.org/10.1007/s12105-022-01507-9CrossRefPubMed

37.

Zhou S, Sun G, Wang J, Zhang H (2020) Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review. Trans Androl Urol 9:2855–2861. https://doi.org/10.21037/tau-20-1343

38.

Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15:55–64. https://doi.org/10.1038/nrc3844CrossRefPubMed

39.

Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP (2010) VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221:125–138. https://doi.org/10.1002/path.2689CrossRefPubMed

40.

go back to reference Cancer Genome Atlas Research N, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374:135–145. https://doi.org/10.1056/NEJMoa1505917CrossRef Cancer Genome Atlas Research N, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374:135–145. https://doi.org/10.1056/NEJMoa1505917CrossRef

41.

Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W (2022) Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma. Eur Urol. https://doi.org/10.1016/j.eururo.2022.05.029CrossRefPubMedPubMedCentral

42.

Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14:4726–4734. https://doi.org/10.1158/1078-0432.CCR-07-4921CrossRefPubMedPubMedCentral

43.

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, Investigators MK (2021) Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease. N Engl J Med 385:2036–2046. https://doi.org/10.1056/NEJMoa2103425CrossRefPubMedPubMedCentral

44.

Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E (2021) Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med 27:802–805. https://doi.org/10.1038/s41591-021-01324-7CrossRefPubMedPubMedCentral

45.

Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D’Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS (2023) Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 24:553–562. https://doi.org/10.1016/S1470-2045(23)00097-9CrossRefPubMed

46.

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ, Consortium TRR (2018) Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal. Cell 173:611-623 e617. https://doi.org/10.1016/j.cell.2018.02.020

47.

Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI, Watkins TBK, Nicol D, Stares M, Challacombe B, Hazell S, Chandra A, Mitchell TJ, Au L, Eichler-Jonsson C, Jabbar F, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Stewart A, Xing W, Smith JC, Escudero M, Huffman A, Matthews N, Elgar G, Phillimore B, Costa M, Begum S, Ward S, Salm M, Boeing S, Fisher R, Spain L, Navas C, Gronroos E, Hobor S, Sharma S, Aurangzeb I, Lall S, Polson A, Varia M, Horsfield C, Fotiadis N, Pickering L, Schwarz RF, Silva B, Herrero J, Luscombe NM, Jamal-Hanjani M, Rosenthal R, Birkbak NJ, Wilson GA, Pipek O, Ribli D, Krzystanek M, Csabai I, Szallasi Z, Gore M, McGranahan N, Van Loo P, Campbell P, Larkin J, Swanton C, Consortium TRR (2018) Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell 173:595-610 e511. https://doi.org/10.1016/j.cell.2018.03.043

48.

Quddus MB, Pratt N, Nabi G (2019) Chromosomal aberrations in renal cell carcinoma: an overview with implications for clinical practice. Urol Ann 11:6–14. https://doi.org/10.4103/UA.UA_32_18CrossRefPubMedPubMedCentral

49.

Nagao K, Yoshihiro S, Matsuyama H, Yamaguchi S, Oba K, Naito K (2002) Clinical significance of allelic loss of chromosome region 5q22.3 approximately q23.2 in nonpapillary renal cell carcinoma. Cancer Genet Cytogenet 136:23–30. https://doi.org/10.1016/s0165-4608(02)00511-3CrossRefPubMed

50.

Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, Mankinen CB, Perlman EJ (2001) A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 158:2089–2096. https://doi.org/10.1016/S0002-9440(10)64680-9CrossRefPubMedPubMedCentral

51.

Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029CrossRefPubMed

52.

Hemesath TJ, Steingrimsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, Arnheiter H, Copeland NG, Jenkins NA, Fisher DE (1994) microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 8:2770–2780. https://doi.org/10.1101/gad.8.22.2770CrossRefPubMed

53.

Argani P (2022) Translocation carcinomas of the kidney. Genes Chromosomes Cancer 61:219–227. https://doi.org/10.1002/gcc.23007CrossRefPubMed

54.

Caliò A, Harada S, Brunelli M, Pedron S, Segala D, Portillo SC, Magi-Galluzzi C, Netto GJ, Mackinnon AC, Martignoni G (2021) TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. Mod Pathol 34:842–850. https://doi.org/10.1038/s41379-020-00713-6CrossRefPubMed

55.

Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M (2005) Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 29:230–240. https://doi.org/10.1097/01.pas.0000146007.54092.37CrossRefPubMed

56.

Xia Q-Y, Wang X-T, Fang R, Wang Z, Zhao M, Chen H, Chen N, Teng X-D, Wang X, Wei X, Ye S-B, Li R, Ma H-H, Lu Z-F, Zhou X-J, Rao Q (2020) Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol 44:477–489. https://doi.org/10.1097/pas.0000000000001408CrossRefPubMed

57.

Williamson SR, Grignon DJ, Cheng L, Favazza L, Gondim DD, Carskadon S, Gupta NS, Chitale DA, Kalyana-Sundaram S, Palanisamy N (2017) Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis? Am J Surg Pathol 41:287–298. https://doi.org/10.1097/pas.0000000000000776CrossRefPubMed

58.

Argani P, Reuter VE, Zhang L, Sung Y-S, Ning Y, Epstein JI, Netto GJ, Antonescu CR (2016) TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol 40:1484–1495. https://doi.org/10.1097/pas.0000000000000720CrossRefPubMedPubMedCentral

59.

Harada S, Caliò A, Janowski KM, Morlote D, Rodriguez Pena MD, Canete-Portillo S, Harbi D, DeFrank G, Magi-Galluzzi C, Netto GJ, Martignoni G, Mackinnon AC (2021) Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas. Mod Pathol 34:2055–2063. https://doi.org/10.1038/s41379-021-00858-yCrossRefPubMed

60.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925. https://doi.org/10.1038/nrm1261CrossRefPubMed

61.

Zbar B, Glenn G, Merino M, Middelton L, Peterson J, Toro J, Coleman J, Pinto P, Schmidt LS, Choyke P, Linehan WM (2007) Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol 177:461–465; discussion 465. https://doi.org/10.1016/j.juro.2006.09.037

62.

Albiges L, Heng DYC, Lee JL, Walker S, Mellemgaard A, Ottesen L, Frigault MM, L’Hernault A, Wessen J, Choueiri T, Cancel M, Signoretti S (2022) Impact of MET status on treatment outcomes in papillary renal cell carcinoma: a pooled analysis of historical data. Eur J Cancer 170:158–168. https://doi.org/10.1016/j.ejca.2022.04.021CrossRefPubMed

63.

Chami R, Yin M, Marrano P, Teerapakpinyo C, Shuangshoti S, Thorner PS (2015) BRAF mutations in pediatric metanephric tumors. Hum Pathol 46:1153–1161. https://doi.org/10.1016/j.humpath.2015.03.019CrossRefPubMed

64.

Wobker SE, Matoso A, Pratilas CA, Mangray S, Zheng G, Lin MT, Debeljak M, Epstein JI, Argani P (2019) Metanephric adenoma-epithelial Wilms tumor overlap lesions: an analysis of BRAF Status. Am J Surg Pathol 43:1157–1169. https://doi.org/10.1097/PAS.0000000000001240CrossRefPubMed

65.

Argani P, Lee J, Netto GJ, Zheng G, Tseh-Lin M, Park BH (2016) Frequent BRAF V600E mutations in metanephric stromal tumor Am. J Surg Pathol 40:719–722. https://doi.org/10.1097/PAS.0000000000000603CrossRef

66.

Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L (2003) Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol 16:1053–1059. https://doi.org/10.1097/01.MP.0000090924.90762.94CrossRefPubMed

67.

Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, Kovacs G (1998) Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17:733–739. https://doi.org/10.1038/sj.onc.1201983CrossRefPubMed

68.

DiNatale RG, Gorelick AN, Makarov V, Blum KA, Silagy AW, Freeman B, Chowell D, Marcon J, Mano R, Sanchez A, Attalla K, Weng S, Voss M, Motzer RJ, Russo P, Coleman JA, Reuter VE, Chen YB, Chan TA, Reznik E, Tickoo SK, Hakimi AA (2021) Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: an emerging entity with variable clinical course. European Urol Focus 7:381–389. https://doi.org/10.1016/j.euf.2019.11.013CrossRef

69.

Batavia AA, Rutishauser D, Sobottka B, Schraml P, Beerenwinkel N, Moch H (2023) Biallelic ELOC-inactivated renal cell carcinoma: molecular features supporting classification as a distinct entity. Mod Pathol 36:100194. https://doi.org/10.1016/j.modpat.2023.100194CrossRefPubMed

70.

Presti JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, Waldman F (2002) Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 167:1464–1468CrossRefPubMed

71.

Kim WY, Sharpless NE (2006) The regulation of INK4/ARF in cancer and aging. Cell 127:265–275. https://doi.org/10.1016/j.cell.2006.10.003CrossRefPubMed

72.

Popov N, Gil J (2010) Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 5:685–690. https://doi.org/10.4161/epi.5.8.12996CrossRefPubMedPubMedCentral

73.

Yang C, Cimera RS, Aryeequaye R, Jayakumaran G, Sarungbam J, Al-Ahmadie HA, Gopalan A, Sirintrapun SJ, Fine SW, Tickoo SK, Epstein JI, Reuter VE, Zhang Y, Chen YB (2021) Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Mod Pathol 34:445–456. https://doi.org/10.1038/s41379-020-00667-9CrossRefPubMed

74.

Mieulet V, Lamb RF (2010) Tuberous sclerosis complex: linking cancer to metabolism. Trends Mol Med 16:329–335. https://doi.org/10.1016/j.molmed.2010.05.001CrossRefPubMed

75.

Mehra R, Vats P, Cao X, Su F, Lee ND, Lonigro R, Premkumar K, Trpkov K, McKenney JK, Dhanasekaran SM, Chinnaiyan AM (2018) Somatic bi-allelic Loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma. Eur Urol 74:483–486. https://doi.org/10.1016/j.eururo.2018.06.007CrossRefPubMedPubMedCentral

76.

He H, Trpkov K, Martinek P, Isikci OT, Maggi-Galuzzi C, Alaghehbandan R, Gill AJ, Tretiakova M, Lopez JI, Williamson SR, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Pivovarcikova K, Michalova K, Slouka D, Prochazkova K, Hora M, Bonert M, Michal M, Hes O (2018) “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch. 473:725–738. https://doi.org/10.1007/s00428-018-2456-4CrossRefPubMed

77.

Chen YB, Mirsadraei L, Jayakumaran G, Al-Ahmadie HA, Fine SW, Gopalan A, Sirintrapun SJ, Tickoo SK, Reuter VE (2019) Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol 43:121–131. https://doi.org/10.1097/PAS.0000000000001170CrossRefPubMedPubMedCentral

78.

Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T (2020) Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol 44:943–954. https://doi.org/10.1097/PAS.0000000000001457CrossRefPubMed

79.

de Oliveira D, Dall’Oglio MF, Reis ST, Zerati M, Souza IC, Leite KR, Srougi M (2014) Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma. Urol Oncol 32:601–606. https://doi.org/10.1016/j.urolonc.2013.12.008CrossRefPubMed

80.

Worby CA, Dixon JE (2014) Pten. Annu Rev Biochem 83:641-669. https://doi.org/10.1146/annurev-biochem-082411-113907

81.

Gupta S, Erickson LA (2020) Renal neoplasia in Cowden Syndrome. Mayo Clin Proc 95:2808–2809. https://doi.org/10.1016/j.mayocp.2020.09.016CrossRefPubMed

82.

Nuevo-Tapioles C, Philips MR (2022) The role of KRAS splice variants in cancer biology. Front Cell Dev Biol 10:1033348. https://doi.org/10.3389/fcell.2022.1033348CrossRefPubMedPubMedCentral

83.

Tong K, Zhu W, Fu H, Cao F, Wang S, Zhou W, Liu C, Chen D, Fan S, Hu Z (2020) Frequent KRAS mutations in oncocytic papillary renal neoplasm with inverted nuclei. Histopathology 76:1070–1083. https://doi.org/10.1111/his.14084CrossRefPubMed

84.

Lobo J, Ohashi R, Helmchen BM, Rupp NJ, Ruschoff JH, Moch H (2021) The morphological spectrum of papillary renal cell carcinoma and prevalence of provisional/emerging renal tumor entities with papillary growth. Biomedicines 9. https://doi.org/10.3390/biomedicines9101418

85.

Kim SS, Cho YM, Kim GH, Kee KH, Kim HS, Kim KM, Kim JH, Choi C (2020) Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma. Mod Pathol 33:690–699. https://doi.org/10.1038/s41379-019-0420-8CrossRefPubMed

86.

Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use Cold Spring. Harb Perspect Biol 2:a001008. https://doi.org/10.1101/cshperspect.a001008CrossRef

87.

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, Nicol D, O'Brien T, Larkin J, Horswell S, Stares M, Au L, Jamal-Hanjani M, Challacombe B, Chandra A, Hazell S, Eichler-Jonsson C, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Jabbar F, Spain L, Lall S, Guarch R, Falzon M, Proctor I, Pickering L, Gore M, Watkins TBK, Ward S, Stewart A, DiNatale R, Becerra MF, Reznik E, Hsieh JJ, Richmond TA, Mayhew GF, Hill SM, McNally CD, Jones C, Rosenbaum H, Stanislaw S, Burgess DL, Alexander NR, Swanton C, Peace, Consortium TRR (2018) Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173:581–594 e512. https://doi.org/10.1016/j.cell.2018.03.057

88.

go back to reference Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AAM, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MDM, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YSN, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJM, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen Y-B, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374:135–145. https://doi.org/10.1056/NEJMoa1505917CrossRefPubMed Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AAM, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MDM, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YSN, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJM, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen Y-B, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374:135–145. https://doi.org/10.1056/NEJMoa1505917CrossRefPubMed

89.

Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S (2019) The genetic changes of Wilms tumour. Nat Rev Nephrol 15:240–251. https://doi.org/10.1038/s41581-019-0112-0CrossRefPubMed

90.

Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387–402. https://doi.org/10.1016/s1535-6108(03)00079-5CrossRefPubMed

91.

Balint I, Szponar A, Jauch A, Kovacs G (2009) Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype. J Clin Pathol 62:892–895. https://doi.org/10.1136/jcp.2009.066423CrossRefPubMed

92.

Cooper GW, Hong AL (2022) SMARCB1-deficient cancers: novel molecular insights and therapeutic vulnerabilities. Cancers (Basel) 14. https://doi.org/10.3390/cancers14153645

93.

Agaimy A (2014) The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol 21:394–410. https://doi.org/10.1097/PAP.0000000000000038CrossRefPubMed

94.

Agaimy A, Amin MB, Gill AJ, Popp B, Reis A, Berney DM, Magi-Galluzzi C, Sibony M, Smith SC, Suster S, Trpkov K, Hes O, Hartmann A (2018) SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients. Hum Pathol 77:139–146. https://doi.org/10.1016/j.humpath.2018.04.004CrossRefPubMed

95.

Cheng L, Xu Y, Song H, Huang H, Zhuo D (2020) A rare entity of primary Ewing sarcoma in kidney. BMC Surg 20:280. https://doi.org/10.1186/s12893-020-00948-9CrossRefPubMedPubMedCentral

96.

Alghamdi MHA, Alawad SA, Alharbi MG, Alabdulsalam AK, Almodhen F, Alasker A (2020) A rare case of Ewing’s sarcoma of the kidney. Urol Case Reports 29:101094. https://doi.org/10.1016/j.eucr.2019.101094CrossRef

97.

Risi E, Iacovelli R, Altavilla A, Alesini D, Palazzo A, Mosillo C, Trenta P, Cortesi E (2013) Clinical and pathological features of primary neuroectodermal tumor/ewing sarcoma of the kidney. Urology 82:382–386. https://doi.org/10.1016/j.urology.2013.04.015CrossRefPubMed

98.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O (2013) Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res. 41:8853–8871. https://doi.org/10.1093/nar/gkt678CrossRefPubMedPubMedCentral

99.

Fukuda H, Kato I, Furuya M, Tanaka R, Takagi T, Kondo T, Nagashima Y (2019) A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion. Virchows Arch 474:389–393. https://doi.org/10.1007/s00428-018-2509-8CrossRefPubMed

100.

Lang M, Vocke CD, Ricketts CJ, Metwalli AR, Ball MW, Schmidt LS, Linehan WM (2021) Clinical and molecular characterization of microphthalmia-associated transcription factor (MITF)-related renal cell carcinoma. Urology 149:89–97. https://doi.org/10.1016/j.urology.2020.11.025CrossRefPubMed

101.

Perret R, Lefort F, Bernhard JC, Baud J, Le Loarer F, Yacoub M (2022) Thyroid-like follicular renal cell carcinoma with sarcomatoid differentiation and an aggressive clinical course: a case report confirming the presence of the EWSR1::PATZ1 fusion gene. Histopathology 80:745–748. https://doi.org/10.1111/his.14589CrossRefPubMed

102.

Eble JNSG, Epstein J, Sesterhenn I (2004) World Health Organization classification of tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. ed. 3

103.

Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, Epstein JI, Netto GJ, Argani P (2014) Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol 27:875–886. https://doi.org/10.1038/modpathol.2013.208CrossRefPubMed

104.

Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan C-L, Sethunath V, Carvalho FLF, Imamovic A, Ricker C, Vokes NI, Nyman J, Berchuck JE, Park J, Hirsch MS, Haq R, Mary Lee G-S, McGregor BA, Chang SL, Feldman AS, Wu CJ, McDermott DF, Heng DYC, Signoretti S, Van Allen EM, Choueiri TK, Viswanathan SR (2022) Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports 38:110190. https://doi.org/10.1016/j.celrep.2021.110190CrossRefPubMed

105.

Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM (2014) Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers Nature reviews. Urology 11:465–475. https://doi.org/10.1038/nrurol.2014.162CrossRefPubMed

106.

Rizzo M, Pezzicoli G, Santoni M, Caliò A, Martignoni G, Porta C (2022) MiT translocation renal cell carcinoma: a review of the literature from molecular characterization to clinical management. Biochimica et Biophysica Acta (BBA) - Rev Cancer 1877:188823. https://doi.org/10.1016/j.bbcan.2022.188823

107.

Tretiakova MS, Wang W, Wu Y, Tykodi SS, True L, Liu YJ (2020) Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological features. Genes Chromosomes Cancer 59:40–49. https://doi.org/10.1002/gcc.22798CrossRefPubMed

108.

Argani P, Zhang L, Reuter VE, Tickoo SK, Antonescu CR (2017) RBM10-TFE3 renal cell carcinoma: a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH. Am J Surg Pathol 41:655–662. https://doi.org/10.1097/pas.0000000000000835CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genomic alterations and diagnosis of renal cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Molecular features for timely cancer diagnosis and treatment – tumors of the ovary, fallopian tube and endometrium

The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review

Molecular pathology in breast disease: diagnostic, prognostic, and therapeutic tools

Molecular diagnostics of hepatobiliary and pancreatic neoplasias

Correction to: Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers